Inhibition of CYP51A1, either pharmacologically (e.g., with ketoconazole) or genetically, reduces DCP accumulation, reprograms the immune microenvironment, and suppresses MSS CRC progression
Despite substantial mechanistic and preclinical evidence indicating neuroprotective effects, translating these findings into clinical benefits has proven challenging
By supporting these pathways, glutathione may help the body process and excrete excess estrogen more efficiently, potentially reducing the hormonal stimulation that fuels fibroid growth
The majority of the replicated, citable preclinical evidence for BPC-157 in tendon, ligament, muscle and cardiovascular models uses IP or IM routes
Gastroenterology 140 , 903912 (2011)